# Labcorp to Acquire BioReference Assets From OPKO for Up to $872 Million

- URL: https://stocks.freetheai.org/news/labcorp-to-acquire-bioreference-assets-from-opko-for-up-to-872-million-44aa70
- Published: 2026-10-15T12:02:25Z
- Category: mergers; sentiment: bullish; impact: medium
- Symbols: [NYSE:LH](https://stocks.freetheai.org/symbols/NYSE-LH), [NASDAQ:OPK](https://stocks.freetheai.org/symbols/NASDAQ-OPK)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Labcorp Holdings Inc. (LH) has agreed to acquire select assets of BioReference Health LLC, a subsidiary of OPKO Health, Inc. (OPK), in a deal valued at up to $872 million. Under the agreement, Labcorp will pay $722 million in cash upfront, which is subject to adjustments based on revenue at closing, alongside up to $150 million in potential earnout payments.

The transaction includes BioReference Health's laboratory testing businesses for clinical and women's health, urology, and corrections, as well as operational assets and more than 80 patient service centers. Labcorp will also acquire the FDA-approved 4Kscore Test used to detect prostate cancer. The company expects these assets to generate approximately $250 million in revenue during the first year after closing.

Investors will be watching the final closing adjustments and the integration of the testing business into Labcorp's existing operations. Following the deal announcement, OPKO Health stock moved higher in premarket trading while Labcorp shares held steady.

## Key points

- Labcorp Holdings Inc. agreed to buy select BioReference Health assets from OPKO Health, Inc. for up to $872 million.
- The deal terms include $722 million in upfront cash and up to $150 million in earnouts based on 4Kscore Test revenue.
- Acquired assets include over 80 patient service centers, urology and clinical testing services, and an FDA-approved prostate cancer test.
- Labcorp expects the acquired assets to generate about $250 million in revenue during the first year post-closing.

## Questions and answers

### How much is Labcorp paying for OPKO's BioReference Health assets?

Labcorp is paying $722 million in upfront cash, with up to $150 million in additional earnout payments based on revenue from the 4Kscore Test, bringing the total potential deal value to $872 million.

### What assets is Labcorp acquiring from BioReference Health?

Labcorp is acquiring clinical and women's health testing services, urology, corrections testing, over 80 patient service centers, operational assets, and the FDA-approved 4Kscore Test for prostate cancer detection.

### How much revenue does Labcorp expect from the acquired assets?

Labcorp forecasts that the acquired BioReference Health assets will generate approximately $250 million in revenue in the first year after the transaction closes.